Biotech Stock News (STEM) (SRPT)

StemCells Inc. (NASDAQ:STEM) On Tuesday May 31, 2016 shares of Stemcells fell by more than 83% after the company announced that it would completely stop its phase 2 Pathway study. The phase 2 study used Stem’s HuCNS-SC human neural stem cells to treat spinal cord injury. This was a huge shock for investors, because the … Read more

Biotech Stock News (RXII) (SRPT)

Rxi Pharmaceuticals (NASDAQ:RXII) On Tuesday April 19, 2016 Rxi Pharmaceuticals announced that it would present pre-clinical data at a medical conference, known as 2016 ARVO Conference. ARVO stands for Association for Research in Vision and Ophthalmology. The pre-clinical data to be presented will be the company’s drug in corneal scarring. In order to prevent injury … Read more

Biotech Stock News (CLDX) (SRPT)

Celldex Therapeutics (NASDAQ:CLDX) On Monday March 7, 2016 shares of Celldex fell as much as 53% after the company announced that it had to discontinue a phase 3 trial. The reason for discontinuing the trial was because of insufficient efficacy needed to move on. This phase 3 trial recruited a total of 745 patients who … Read more

Biotech Stock News (SRPT) (JUNO) (CELG) (AGTC) (VRTX)

Sarepta Therapeutics (NASDAQ:SRPT) On Monday June 29, 2015 Sarepta had announced that it had completed¬†its rolling submission of its New Drug Application — NDA — to the FDA. A rolling submission is an FDA policy whereby biotech companies can submit their marketing approval application in small parts on a rolling basis instead of doing it … Read more

Biotech Stock News (SRPT) (BMRN) (PBMD) (ISR)

Sarepta Therapeutics (NASDAQ:SRPT) After the closing bell on May 19, 2015 shares of Sarepta Therapeutics were up as much as 38% in after-hours trading after the company reported that the FDA will allow the company to file a New Drug Application — NDA — for Eteplirsen. This drug Eteplirsen helps patients with Duchenne Muscular Dystrophy … Read more

Biotech Stock News (HZNP)(HPTX)(XON)(SRPT)(MDVN)(ALPMY)(AZN)

Horizon Pharma (NASDAQ:HZNP) Shares of Horizon Pharma ended the day up 18% on March 30, 2015 after the company announced that it would acquire Hyperion Therapeutics (NASDAQ:HPTX) for $955.7 million dollars. Although one thing to note is that this deal for $955.7 million dollars will be a mix of a cash and debt deal. The … Read more